2023-05-17 09:07:40 ET
Breast implant maker Sientra, Inc. ( NASDAQ: SIEN ) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted a 510(k) clearance for its Portfinder Technology, used in plastic surgery. Sientra ( SIEN ) shares added ~18% in reaction.
Portfinder is a handheld device used by surgeons to locate the ports in Sientra’s ( SIEN ) breast tissue expanders, Dermaspan and AlloX2 Pro. Unlike the traditional dangle magnet mechanism, Portfinder Technology allows for more accurate port location.
“The Portfinder™’s unique interactive screen guides the user towards the center of the ports and allows for precise identification and marking of both fill and drain ports in Dermaspan® and AlloX2® Pro expanders, making it a very versatile device”, SIEN’s Chief Technical Officer Dr. Denise Dajles remarked.
“We look forward to commercializing this product and putting it in the hands of the most skilled plastic surgeons, our customers,” Chief Executive Ron Menezes added.
More on Sientra
- Sientra GAAP EPS of -$1.06 beats by $0.16, revenue of $22.56M misses by $0.35M
- Aziyo, Sientra team up to expand distribution of SimpliDerm
For further details see:
Sientra wins FDA nod for Portfinder Technology